$XBI $75.92| -1.0%
Table of Contents:
Covid Updates
$
Pipeline Updates
$SQZ -5.1% SQZ Biotechnologies Receives FDA Fast Track Designation for its Lead Cell Therapy Candidate for the Treatment of HPV16+ Tumors source
$SIOX -23.7% Sio Gene Therapies Provides Corporate Update source
$ANAB -0.9% ANAPTYSBIO ANNOUNCES POSITIVE ANB032 (ANTI-BTLA AGONIST) TOP-LINE PHASE 1 DATA AND PROVIDES PIPELINE UPDATES source
$ACET +6.8% Adicet Bio Announces Oral Presentation of Updated ADI-001 Phase 1 Data at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting source
$EVFM +1.8% Evofem Improves Phexxi® Patient Experiences Through New Agreement with VitaCare Prescription Services source
$HRMY -1.7% HARMONY BIOSCIENCES INITIATES PHASE 3 TRIAL OF PITOLISANT IN ADULT PATIENTS WITH IDIOPATHIC HYPERSOMNIA source
$ALLO -0.8% Allogene Therapeutics Receives FDA Orphan-Drug Designation for ALLO-605, its First TurboCAR™ T Cell Product Candidate, for the Treatment of Multiple Myeloma source
$PFE (+1.5%) & $BHVN (+0.7%) PFIZER AND BIOHAVEN’S VYDURA® (RIMEGEPANT) GRANTED FIRST EVER MARKETING AUTHORIZATION BY EUROPEAN COMMISSION FOR BOTH ACUTE TREATMENT OF MIGRAINE AND PROPHYLAXIS OF EPISODIC MIGRAINE source
$SLDB -17.0% Solid Biosciences Announces Updated Corporate Strategy to Develop SGT-001 and SGT-003 Pipeline Programs for Patients with Duchenne Muscular Dystrophy source
$BCRX +4.7% European Medicines Agency Grants PRIME Designation to BioCryst’s ALK-2 Inhibitor, BCX9250, for Treatment of Fibrodysplasia Ossificans Progressiva source
$GMDA -7.1% Gamida Cell Presents Updated One-Year Post-Transplant Follow Up Data from Phase 3 Study of Omidubicel at 2022 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR Tandem Meetings source
$FENC -9.3% FENNEC PHARMACEUTICALS ANNOUNCES FDA ACCEPTANCE FOR FILING OF NEW DRUG APPLICATION RESUBMISSION FOR PEDMARK™ source
Want to get weekly catalyst updates?
*We never spam you - unsubscribe anytime*
Business Updates
$HTBX -1.8% Heat Biologics (NightHawk Biosciences) Announces that its Elusys Therapeutics Subsidiary has Executed a Contract to Deliver ANTHIM® to the Canadian Government source
$ZNTL +11.8% ZENTALIS PHARMACEUTICALS ANNOUNCES $25 MILLION EQUITY INVESTMENT FROM PFIZER source
Posted by JM
Comments